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ABSTRACT
Introduction: “Incretin-based” therapies, such 
as the glucagon-like peptide-1 (GLP-1) receptor 
agonists, represent a major advance in type 2 
diabetes mellitus (T2DM) treatment. GLP-1 
receptor agonists differ substantially in their 
duration of action, frequency of administration 
and clinical profile.
Methods: This article reviews the mechanisms of 
action and clinical evidence for GLP-1 receptor 
targeting and discusses differences between 
GLP-1 therapies, focusing particularly on clinical 
data for the GLP-1 receptor agonist, lixisenatide.
Results: GLP-1 therapies target islet cell 
“defects” of insufficient insulin and excessive 
glucagon secretion in T2DM, in a glucose-
dependent manner, with minimal risk of 
hypoglycemia. Different GLP-1 therapies exert 
differential effects on fasting and postprandial 
glycemia (both being major determinants 
of glycemic control). They also slow gastric 
emptying to different extents, probably 
accounting for different effects to reduce 
postprandial glycemia. The GetGoal phase 3 
studies in T2DM have confirmed the efficacy 
of once-daily lixisenatide in reducing plasma 
glucose and glycated hemoglobin (HbA1c), 
with a pronounced lowering of postprandial 
plasma glucose (PPG), as monotherapy and 
as add-on to oral antidiabetic drugs and 
to basal insulin. Lixisenatide’s ability to 
diminish PPG is probably partly mediated by 
its marked ability to delay gastric emptying. 
Lixisenatide is generally well tolerated, with 
possibly better gastrointestinal tolerability and 
lower risk of hypoglycemia than exenatide 
immediate release. Lixisenatide is associated 
with a beneficial effect on weight, with either 
no change or a decrease in body weight when 
administered as add-on therapy to basal insulin 
in overweight patients with T2DM.
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glucose load [3, 4]. In healthy individuals, this 
so-called “incretin effect” accounts for 50−70% 
of postprandial insulin secretion [5]. The two 
known incretin hormones are GLP-1 (secreted 
predominantly from the distal small intestine 
and colon) and gastrointestinal insulinotropic 
polypeptide (GIP; secreted mainly from the 
proximal small intestine). The insulinotropic 
property of GIP was documented in 1973 [6] and 
that of GLP-1 in 1985 [7]. The release of incretin 
hormones is stimulated by the interaction of 
nutrients (and also bile salts in the case of GLP-1) 
with the intestine. Both are rapidly degraded 
in the circulation by a ubiquitous enzyme 
called DPP-4, so that the plasma half-life of 
the active molecules is only a few minutes 
[8, 9]. In 1986, Nauck and colleagues [10] reported 
that the magnitude of the incretin effect was 
diminished in patients with T2DM. While this 
may potentially represent an epiphenomenon 
of pancreatic beta-cell failure, it is clear that the 
secretion of both GIP and GLP-1 is relatively 
intact in T2DM; but while the insulinotropic 
property of GLP-1 is preserved, that of GIP is 
markedly diminished, probably partly as an 
effect of hyperglycemia [11]. Pharmaceutical 
development has thus hitherto focused primarily 
on agents based on the action of GLP-1, 
i.e., DPP-4 inhibitors and GLP-1 receptor 
agonists, which are resistant to degradation 
by DPP-4 [12]. A fundamental advantage of 
GLP-1-based therapy is that it targets the islet cell 
“defects” of insufficient insulin, and excessive 
glucagon, secretion in T2DM. Importantly, the 
insulinotropic and glucagonostatic properties 
of GLP-1 are glucose-dependent, with a 
threshold for these effects of approximately 
8 mmol/L, so that there is minimal, if any, risk 
of hypoglycemia. These drugs also target fasting, 
as well as pre and postprandial glycemia; the 
latter is now recognized as a major determinant 
of “average” glycemic control, as assessed by 
Conclusions: Lixisenatide improves glycemic 
control, by primarily affecting PPG, while 
preventing weight gain or reducing body weight 
with a low risk of hypoglycemia in T2DM. 
Lixisenatide is likely to represent a significant 
advance in the management of T2DM, perhaps 
particularly in those patients with relatively 
faster gastric emptying and lower levels of HbA1c, 
including those receiving basal insulin.
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INTRODUCTION
A number of therapeutic options are available 
for the management of type 2 diabetes mellitus 
(T2DM), as indicated by the recent American 
Diabetes Association/European Association 
for the Study of Diabetes guidelines [1]. These 
therapies are associated with different adverse 
effects; notably, the use of insulin and insulin 
secretagogs is associated with an increased 
propensity for hypoglycemia and weight gain [2]. 
The recent availability of “incretin-based” 
therapies, comprising of dipeptidyl peptidase-4 
(DPP-4) inhibitors and glucagon-like peptide-1 
(GLP-1) receptor agonists, represents a major 
advance given that these drugs do not increase 
the risk of hypoglycemia significantly. DPP-4 
inhibitors are weight neutral, while the use 
of GLP-1 receptor agonists is associated with 
modest weight loss [1, 2]. The development of 
these drugs has followed the recognition that 
the incretin system is pivotal to the regulation 
of blood glucose homeostasis. It was reported in 
1964 that the insulin response to an enteral, or 
oral, glucose load is substantially greater than 
that induced by an iso-glycemic intravenous 
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and GLP-1 receptors are expressed widely 
throughout multiple body systems, including 
the pancreas, brain, heart, kidney, and 
gastrointestinal tract.
It has generally been assumed that GLP-1 
regulates glucose homeostasis through 
effects on islet cell function [16–18], which 
are certainly important, especially in 
relation to the glucose dependency of the 
insulinotropic and glucagonostatic properties 
of GLP-1 [19], and are of particular relevance 
to fasting glycemia. However, because 
the human stomach empties at an overall 
rate of 1−4 kcal/min in health [20, 21], 
most humans are predominantly in the 
postprandial or postabsorptive state, with the 
duration of fasting limited, in most cases, to 
perhaps about 4 h before breakfast. Moreover, 
gastric empting is often abnormally delayed 
(and occasionally, more rapid) in patients 
with T2DM and is a major determinant of 
postprandial glycemia [22–24]. In T2DM 
patients with delayed emptying, the magnitude 
of this delay is often modest [22–24], hence 
the fact that both endogenous and exogenous 
GLP-1 slow gastric emptying is of fundamental 
significance. Moreover, the secretion of GLP-1 is 
dependent on the small intestinal glucose load 
being released in much greater amounts when 
the rate of carbohydrate exposure is at the upper 
end of the normal physiological range [25]. 
Using the GLP-1 receptor antagonist, exendin 
(9–39), it was shown that endogenous GLP-1 is a 
physiologic modulator of gastric emptying [26]. 
When GLP-1 was administered exogenously 
to healthy individuals [27, 28] and patients 
with T2DM [29], there was an overall marked 
(but variable) slowing of gastric emptying. 
The reduction in postprandial glycemia 
induced by acute administration of GLP-1 
was shown to be related to the magnitude 
of the slowing of gastric emptying [28]; 
glycated hemoglobin (HbA1c), particularly 
as glycemic control improves [1]. Several 
GLP-1 receptor agonists are available and are 
increasingly used both as monotherapy and as 
“add-on” to other agents, particularly metformin, 
and more recently, basal insulin [13–15]. 
Unlike DPP-4 inhibitors (which are administered 
orally), there are substantial differences 
between GLP-1 receptor agonists (which are 
administered subcutaneously) in terms of their 
duration of action and consequent frequency 
of administration.
This review addresses the mechanisms of 
action and clinical efficacy of GLP-1 receptor 
agonists, with a particular focus on a novel agent 
in this class, lixisenatide.
METHODS
Pubmed was searched for English language 
articles that evaluated the pharmacokinetics, 
efficacy, safety and mode of action of lixisenatide 
(without time limits). The search parameters 
were “glucagon-like peptide-1 receptor agonists,” 
“lixisenatide,” “efficacy,” “safety,” “mechanism 
of action,” and “pharmacokinetics.” Original 
research articles, reviews and other articles of 
interest were reviewed. References of key reviews 
were also reviewed to ensure that all data 
sources were captured. In addition, a number of 
abstracts and posters on lixisenatide presented at 
key diabetes congresses were also reviewed when 
available in the public domain. From these 
sources, the most important information was 
identified for inclusion in this review. Abstracts 
and posters citing data that are now published 
were excluded from this review.
The GLP-1 Receptor as a Therapeutic Target
GLP-1 receptor agonists target several metabolic 
abnormalities in the T2DM phenotype, 
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the latter is greater when “baseline” gastric 
emptying is relatively more rapid [30]. That 
the reduction in postprandial glycemia induced 
by exogenous GLP-1 is associated with a 
reduction, rather than an increase, in insulin 
indicates that slowing of gastric emptying 
outweighs the insulinotropic property of GLP-1 
in this situation [28, 29, 31]. Not surprisingly, 
administration of the gastrokinetic drug, 
erythromycin, suppressed the GLP-1-induced 
slowing of gastric emptying and attenuated 
its effect to reduce postprandial glycemia [32]. 
Therefore, it is arguable whether or not GLP-1 
should be regarded as a true incretin, at least 
postprandially. A recent study suggests that the 
slowing of gastric emptying by exogenous GLP-1 
may be subject to tachyphylaxis with sustained 
exposure [33]. When two drinks were given 
to healthy individuals at an interval of 4 h, 
GLP-1 slowed gastric emptying of both 
drinks, but the magnitude of the slowing of 
the second drink was less. It was suggested 
that tachyphylaxis may occur at the level of 
the vagus nerve [33]. While the study had 
methodological limitations, the conclusions 
are likely to be valid and of major relevance to 
the effects of different GLP-1 receptor agonists.
GLP-1 is also involved in the regulation of 
appetite and energy intake. For example, in obese 
individuals there was a reduction in hunger and 
food consumption after infusion of GLP-1 [34], 
and in patients with T2DM, a continuous, 
subcutaneous infusion of GLP-1 over a 6-week 
period reduced appetite and resulted in an 
average weight loss of 1.9 kg [35]. Studies in 
animals suggest that GLP-1 has the capacity 
to promote β-cell proliferation [36], inhibit 
apoptosis [37], and thereby preserve or expand 
β-cell mass [38]. It remains to be determined 
whether this is also the case in human T2DM. 
Therefore, GLP-1 has diverse effects of relevance 
to blood glucose homeostasis.
Differences Between GLP-1 Receptor 
Agonists
Three GLP-1 receptor agonists are currently 
approved for the management of T2DM, and 
several agents are in late-stage development. 
Exenatide immediate release (IR) was approved 
in Europe in 2006 and is a “short-acting” GLP-1 
receptor agonist (mean half-life of 2.4 h) given 
as a twice-daily injection 30−60 min before 
the first and last meal of the day [39]. In some 
European countries, exenatide is also available 
as an extended-release formulation, which is 
given as a once-weekly injection [40]. Liraglutide 
was approved in Europe in 2009 and is a “long-
acting” GLP-1 receptor agonist given as a once-
daily injection independent of meals. Liraglutide 
has a half-life of 11–15 h and is designed to 
provide sustained GLP-1 activation throughout 
the day [41] (Table 1) [39, 41–46]. Exenatide, 
a synthetic version of exendin-4, originally 
isolated from the saliva of the Gila monster 
lizard, is a GLP-1 receptor agonist exhibiting 
approximately 53% homology to native GLP-1. 
In contrast, liraglutide is a GLP-1 analog and was 
developed specifically for use in T2DM.
All GLP-1 receptor agonists appear to have 
the same fundamental mode of action on the 
GLP-1 receptor. Meta-analyses and randomized, 
controlled trials indicate that these agents 
improve HbA1c on average by about 1%, with a 
low risk of hypoglycemia, reduce body weight 
by 1−4 kg per annum, and are generally well 
tolerated. Although gastrointestinal adverse 
events (AEs) such as nausea and diarrhea 
are common, in most cases they dissipate 
with ongoing use [47–49]. For example, 
gastrointestinal AEs resolve within 6–8 weeks 
in most patients and both their incidence 
and severity can be reduced using a dose-
escalation strategy [50, 51]. GLP-1 receptors are 
widely expressed in cardiovascular tissue, and 
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cardiovascular effects, particularly a modest 
increase in heart rate, have been reported with 
the use of GLP-1 receptor agonists [50, 52, 53].
GLP-1 receptor agonists exhibit differences 
in their effects on pre and postprandial 
glucose [54]. For example, in a direct 
comparison between liraglutide and exenatide 
IR in patients with T2DM inadequately 
controlled on metformin or sulfonylurea, 
liraglutide 1.8 mg once daily (n = 233) 
reduced mean fasting plasma glucose (FPG) 
versus exenatide (estimated treatment difference 
−1.01 mmol/L; P < 0.0001), while exenatide had 
a greater effect on PPG excursions (breakfast: 
estimated treatment difference 1.33 mmol/L; 
P < 0.0001; dinner: estimated treatment difference 
1.01 mmol/L; P = 0.0005) [51]. These differences 
are likely to reflect the pharmacokinetic profile 
of GLP-1 receptor activation, as a result of the 
impact on the slowing of gastric emptying, and 
hence, postprandial glycemic excursions. As is 
the case with native GLP-1 [30], the magnitude 
of the effect of GLP-1 receptor agonists to 
slow gastric emptying in T2DM appears to be 
dependent on the baseline rate of emptying, 
so that the effect is greater in those with more 
rapid emptying initially [55]. Furthermore, 
the reduction in postprandial glycemia and 
the impact on postprandial insulin induced 
by GLP-1 receptor agonists are related to the 
slowing of gastric emptying [55]. Scintigraphy 
is the “gold standard” technique to quantify 
gastric emptying [56, 57], while the use of stable 
isotope breath tests and ultrasonography are 
acceptable alternatives [57–59]. However, in 
many studies relating to the effect of GLP-1 
receptor agonists on gastric emptying, the latter 
has been assessed using the less-than-optimal 
paracetamol absorption method [42–44, 60]. 
With the latter technique, it has been reported 
in rats that the delay of gastric emptying 
induced by liraglutide diminishes within 
14 days, whereas the comparable initial delay 
induced by exenatide IR is sustained (Fig. 1) [60]. 
In patients with T2DM, after 14 weeks’ 
administrat ion,  exenatide IR s lowed 
paracetamol absorption significantly, while 
exenatide long-acting release (LAR) had 
no significant effect [44]. Liraglutide does, 
however, have a modest effect to delay 
paracetamol absorption after administration 
for 3 weeks in patients with T2DM, which 
correlates with the reduction in postprandial 
glucose [42]. In contrast, exenatide IR has been 
Table 1  Pharmacologic characteristics of currently available GLP-1 receptor agonists and lixisenatide
Drug Administration t1/2 tmax Exposure Sustained eect to slow 
gastric emptying 
Exenatide IR [39] Twice daily 2.4 h 2.1 h Intermittent Yes
Exenatide ER [45] Once weekly 2.4 h 2 weeksa Continuous Minimalb
Liraglutide [41] Once daily 11–15 h 9–12 h Continuous Minimalc
Lixisenatided [46] Once daily 2.8 h 1.25 h Intermittent Yes
ER extended release, GLP-1 glucagon-like peptide-1, IR immediate release, t1/2 terminal half-life, tmax time to maximum 
plasma concentration
a First peak, a second peak occurs at 6−7 weeks
b 75% less ecacy versus exenatide IR in head-to-head study [44]
c Flint et al. [42] and Degn et al. [43] analysis ongoing
d 20 µg dose
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shown to slow gastric emptying markedly in 
T2DM after administration for 5 days, as assessed 
by scintigraphy [55]. These observations are 
presumably attributable to the “tachyphylaxis” 
phenomenon reported by Nauck et al. [33]. 
The implications are that “baseline” gastric 
emptying and the priority for reducing 
postprandial glucose excursions are likely to 
be relevant to the choice of GLP-1 receptor 
agonist in patients with T2DM. This includes 
the potential combination of basal insulin 
and a GLP-1 receptor agonist, for which there 
is a persuasive rationale, i.e., insulin therapy 
primarily targets preprandial glucose and 
causes hypoglycemia and weight gain, while 
some GLP-1 receptor agonists predominantly 
target postprandial glucose by slowing gastric 
emptying, and their use is associated with a 
low risk of hypoglycemia and modest weight 
loss. Therefore, the combined use of basal 
insulin with a GLP-1 receptor agonist has the 
potential to optimize glycemic control, with 
a limited risk of hypoglycemia and without 
weight gain. There is now evidence that this 
approach is effective. For example, in a recent 
study by Buse et al. [53] in patients with T2DM, 
exenatide IR added on to basal insulin glargine 
improved glycemic control substantially, with 
a reduction in HbA1c of 1.74% after 30 weeks’ 
treatment compared with 1.04% with placebo, 




































































Fig. 1  Study in rats demonstrating tachyphylaxis in the slowing of gastric emptying induced by liraglutide, but not exenatide 
IR. Gastric emptying was assessed using a standard acetaminophen release assay. Aer the acute test, rats were dosed twice 
daily for 14 days. (a) Plasma levels of acetaminophen following subcutaneous administration (at t = −30 min) of vehicle, 
liraglutide or exenatide on day 14; (b) AUC(0–180 min). e data show only a slight (~ 5%) inhibition of gastric emptying 
in liraglutide-treated rats, while in exenatide-treated rats, gastric emptying was dramatically reduced. Reproduced with 
permission from Jelsing J, et al. Diabetes Obes Metab. 2012;14:531–8. [60]. aExenatide 3 and 10 μg/kg signicantly dierent 
from vehicle, bexenatide 3 and 10 μg/kg and liraglutide 200 μg/kg signicantly dierent from vehicle (P < 0.05 for both) 
AUC0−180 min area under the curve at 0−180 min, IR immediate release
(a) (b)
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Lixisenatide: A Novel GLP-1 Receptor 
Agonist
Lixisenatide is a new once-daily prandial GLP-1 
receptor agonist that was approved by the 
European Medicines Agency in February 2013 
for the management of T2DM. Lixisenatide is a 
synthetic version of exendin-4 that is resistant 
to degradation by DPP-4 as a result of C-terminal 
modification with six lysine residues and one 
proline deletion [61]. Lixisenatide is unique 
in that it is “short-acting,” but administered 
as a once-daily dose; this is believed to be 
partly due to its marked ability to delay gastric 
emptying (Table 1) [61]. Lixisenatide has now 
been well characterized in pharmacokinetic and 
pharmacodynamic studies and its efficacy and 
safety in patients with T2DM has been evaluated 
in an extensive clinical development program 
known as the GLP-1 agonist AVE0010 in paTients 
with type 2 diabetes mellitus for Glycemic 
cOntrol and sAfety evaLuation (GetGoal) phase 3 
clinical trial program. Notably, this program 
includes a study as add-on to basal insulin in 
Asian patients with T2DM, who often have a 
pathophysiology of insulin deficiency, rather 
than insulin resistance and in whom GLP-1 
secretion may be impaired [62–64].
RESULTS
Pharmacokinetic and Dosing Studies
Lixisenatide exhibits  dose-dependent 
pharmacokinetics. In a 4-week, randomized, 
placebo-controlled, dose-ranging study in 
64 patients with T2DM, using an ascending dose 
range of 5−20 µg once daily (increased every 
fifth day in increments of 2.5 µg), steady-state 
plasma concentrations increased in proportion to 
the dose administered (5 µg, 10 µg, and 20 µg). 
The mean area under the curve (AUC) and peak 
plasma concentration also increased according 
to the dose and dose frequency. Peak plasma 
concentrations were achieved within 1.25–2.25 h 
(depending on dose) [45]. All lixisenatide doses 
(5–20 µg) were associated with decreased AUC 
for PPG versus placebo, with the greatest decrease 
seen for the lixisenatide 20 µg dose. The median 
drug half-life was 2.8 h for lixisenatide 20 µg 
(range 2.7 h in lixisenatide 10 µg once daily to 
4.3 h in lixisenatide 5 µg twice daily) [46] (Table 1).
In a 13-week, dose–response study in 
542 patients with T2DM inadequately controlled 
on metformin, lixisenatide 5–30 µg once or twice 
daily reduced HbA1c levels in a dose-dependent 
manner; respective mean reductions for 5, 10, 20, 
and 30 µg doses were 0.47%, 0.50%, 0.69%, and 
0.76% on once-daily and 0.65%, 0.78%, 0.75%, 
and 0.87% on twice-daily administration versus 
0.18% with placebo (all P < 0.01 vs. placebo). The 
20 µg once-daily dosage demonstrated the best 
efficacy to tolerability ratio [65].
Mechanisms of Efficacy
The mechanisms by which lixisenatide exerts its 
glucose-lowering effect have been investigated in 
several studies, which have demonstrated effects 
of lixisenatide on multiple factors involved in 
glucose regulation [66–68].
Two parallel, single-dose studies demonstrated 
that lixisenatide 20 µg daily restores first and 
second-phase insulin responses and accelerates 
glucose disposition. In both studies, subjects 
received lixisenatide 20 µg or matching 
placebo 2 h before 0.3 g/kg intravenous glucose 
challenge, and insulin secretion was assessed 
by C-peptide deconvolution [66, 67]. In the 
first study, conducted in 20 healthy subjects, 
lixisenatide enhanced first-phase insulin 
secretion (AUC0–10 min) 2.4-fold and second-
phase by (AUC10–120 min) 0.9-fold versus placebo. 
Glucose disposition was also accelerated 2.3-fold, 
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and a reduction in blood glucose below 
counterregulatory thresholds (<3.9 mmol/L) was 
evident in some subjects [66]. The second study 
was conducted in 22 patients with “early-stage” 
T2DM and 20 healthy subjects. In the healthy 
subjects, lixisenatide enhanced first and second-
phase insulin secretion by 2.4 and 0.8-fold versus 
placebo, respectively, while in patients with 
T2DM, lixisenatide enhanced first and second-
phase insulin secretion by 2.8 and 1.6-fold 
versus placebo, respectively. Glucose disposition 
was increased by 2.3 and 1.8 in healthy subjects 
and patients with T2DM, respectively [67].
The comparative efficacy of lixisenatide versus 
liraglutide in reducing PPG concentrations was 
evaluated in a 4-week, randomized, open-label 
study of lixisenatide 20 µg once daily (n = 77) 
versus liraglutide 1.8 mg once daily (n = 71) in 
patients with T2DM suboptimally controlled on 
metformin [52]. The primary endpoint was the 
change in PPG from baseline to week 4 based 
on a standardized breakfast test. Lixisenatide 
administration resulted in greater reductions in 
both PPG (glucose AUC00:30–04:30 h) (P < 0.0001) 
and in maximum PPG excursions versus 
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Fig. 2  Changes in postprandial glucose (AUC00:30−04:30 h) and insulin (AUC00:30−04:30 h) aer 4 weeks’ administration of 
lixisenatide 20 µg once daily, or liraglutide 1.8 mg once daily in patients with T2DM insuciently controlled on metformin. 
At baseline (day −1) and day 28, all participants received a standardized breakfast test (60.6% carbohydrates, 12.4% protein, 
26.9% fat, 451 kcal in total). Patients received lixisenatide 20 μg (n = 77) or liraglutide 1.8 mg (n = 71), both administered 
once daily subcutaneously 30 min before breakfast. Measurements were performed on day −1/day 1 and on day 28/29 over a 
24-h period following breakfast. Aer 4 weeks of treatment, lixisenatide administration resulted in a much greater reduction 
in (a) postprandial plasma glucose and (b) insulin, compared with liraglutide, both P < 0.0001. Reproduced/modied with 
permission from Kapitza C, et al. Poster presented at the 21st World Diabetes Congress, Dubai, UAE, December 8 2011 
(Absract D–0740) [52]. AUC00:30−04:300h area under the curve from 00:30 to 04:30 h; T2DM type 2 diabetes mellitus
(a) (b)
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–2.53 mmol/L [–45.5 mg/dL]; P < 0.0001) (Fig. 2a) 
[52], so that at study end, a greater proportion 
of lixisenatide-treated patients achieved 2-h PPG 
levels <7.77 mmol/L (<140 mg/dL) compared 
with liraglutide-treated patients (69% vs. 29%, 
respectively). Postprandial insulin (Fig. 2b) 
and C-peptide levels were markedly reduced 
with lixisenatide compared with liraglutide 
(P < 0.0001 for both). Lixisenatide also decreased 
post meal glucagon when compared with 
liraglutide (treatment difference –21.2 h.pg/mL; 
P = 0.032). Mean HbA1c and body weight 
decreased in both groups. Both treatments were 
reasonably well tolerated; nausea, diarrhea, and 
vomiting were reported in 22.1%, 2.6%, and 
10.4% of patients for lixisenatide and 22.5%, 
15.5%, and 7.0% for liraglutide, respectively.
Further investigation demonstrated that the 
reduction in PPG observed with lixisenatide 
is accompanied by a substantial slowing of 
gastric emptying, which would account for the 
observed reduction in postprandial insulin. In a 
randomized, double-blind, 4-week trial in patients 
with T2DM, using an ascending dose range of 
5−20 µg once daily or twice daily (increased every 
fifth day in increments of 2.5 µg), lixisenatide 
20 µg reduced PPG after breakfast (P < 0.0001), 
lunch (P < 0.0001), and dinner (P < 0.05) when 
compared with placebo, with proportionally 
greater reductions after breakfast than after 
lunch and dinner when administered in the 
morning. These reductions were accompanied 
by a slowing in gastric emptying of breakfast as 
assessed by 13C-octanoic acid breath test (mean 
change from baseline [± standard deviation (SD)] 
in mean gastric emptying half-emptying 
time –24.1 ± 133.1 min vs. 211.5 ± 278.5 min 
for lixisenatide and placebo, respectively; 
P < 0.01). It should be appreciated that the rate of 
gastric emptying was markedly reduced despite 
glucose lowering, an effect that would favor more 
rapid emptying [69]. Moreover, there was an 
inverse relationship between PPG and the rate of 
gastric emptying with lixisenatide 20 µg (r2 = 0.51; 
P < 0.05) [68], as has been reported to be the case 
with exogenous GLP-1 [28] and exenatide IR [55]. 
Accordingly, lixisenatide, like other GLP-1 receptor 
agonists, has the capacity to stimulate insulin and 
suppress glucagon secretion and also markedly 
reduce postprandial glycemic excursions, probably 
predominantly by slowing gastric emptying.
GetGoal: The Lixisenatide Phase 3 Clinical 
Trial Program
The safety and efficacy of lixisenatide 20 µg 
once daily has been evaluated in adult patients 
with T2DM in the GetGoal phase 3 clinical 
trial program, which was initiated in 2008 and 
has hitherto enrolled more than 5,000 patients 
globally. An overview of available patient 
characteristic data from the studies included in 
the program is shown in Table 2 [62, 70–76]. In 
this series of randomized, placebo-controlled trials, 
lixisenatide was evaluated across the spectrum of 
T2DM care as monotherapy, as add-on therapy to 
metformin, sulfonylureas, or thiazolidinediones, 
and in combination with basal insulin. Three 
studies investigated the combined effects of 
lixisenatide and basal insulin with the rationale 
that targeting both PPG (with lixisenatide) and 
FPG and preprandial plasma glucose (with basal 
insulin) may provide additive effects, leading to 
enhanced glycemic control [62, 70, 71]. In all of 
the completed studies, the efficacy of lixisenatide 
once daily in reducing blood glucose levels, with a 
pronounced effect on PPG, has been demonstrated.
Effect of Lixisenatide as Monotherapy and as 
“Add-On” to Oral Antidiabetic Agents
The effect of lixisenatide on glycemia both 
as monotherapy and as “add-on” to oral 
antidiabetic agents (OADs) has been evaluated 
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in a series of trials, with HbA1c as the primary 
endpoint. These studies have established the 
efficacy of lixisenatide both as monotherapy and 
as add-on to OADs, with an effect of decreasing 
HbA1c comparable with that of exenatide IR, and 
a particularly pronounced effect in reducing 
PPG excursions.
Fasting Plasma Glucose
As monotherapy, lixisenatide administration 
resulted in reductions in FPG versus placebo (least 
squares [LS] mean difference vs. placebo –1.1 mmol/L 
[–19.8 mg/dL]; P < 0.0001 for lixisenatide one-
step titration) [77]. As add-on to metformin, 
lixisenatide, in a morning dose, led to FPG 
reductions of –1.19 (–21.4 mg/dL; P < 0.005 vs. 
placebo) [72]; as add-on to sulfonylurea, to a 
reduction of –0.99 (–17.8 mg/dL; P < 0.0001 vs. 
placebo) [73]; and as add-on to thiazolidinediones, 
to FPG reductions of –0.84 (–15.1 mg/dL; 
P < 0.0001 vs. placebo) [74]. In GetGoal-X versus 
exenatide IR, improvements in mean FPG were 
comparable between lixisenatide once daily 
and exenatide twice daily (LS mean change 
from baseline −1.2 mmol/L [–22 mg/dL] and 
−1.4 mmol/L [–26 mg/dL], respectively) [75].
Postprandial Glucose
As monotherapy in GetGoal-MONO, 
lixisenatide had a pronounced effect on PPG 
associated with breakfast, with improvements 
in 2-h postprandial glucose levels (P < 0.001 vs. 
placebo) and a 75% reduction versus placebo in 
the postprandial glucose excursion, as measured 
during a standardized breakfast (Fig. 3) [77]. 






















































Fig. 3  Changes in 2-h postprandial glucose and 2-h glucose excursion aer 12 weeks of treatment with lixisenatide 20 µg 
two-step (10 µg for 1 week, 15 µg for 1 week, and then 20 µg; n = 120), lixisenatide one-step (10 µg for 2 weeks and then 20 
µg; n = 119), placebo two-step (n = 61), or placebo one-step (n = 61) (placebo groups were combined for analyses). Data 
are from patients with T2DM not receiving glucose-lowering therapy undergoing a standardized breakfast meal. Glucose 
excursion = 2-h PPG, plasma glucose 30 min before the meal test before study drug administration. Lixisenatide one-step 
and two-step titration reduced both 2-h PPG and 2-h glucose excursions versus placebo. Data shown are mean ± SD. 
Reproduced with permission from Fonseca VA, et al. Diabetes Care. 2012;35:1225–31 [77]. PPG postprandial glucose, 
T2DM type 2 diabetes mellitus
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lixisenatide in patients suboptimally controlled 
on metformin in the GetGoal-M study [72] and 
sulfonylureas in the GetGoal-S study [73].
Glycated Hemoglobin
As monotherapy in a 12-week trial (GetGoal-
MONO), lixisenatide administration resulted in 
reductions in HbA1c versus placebo (–0.85 for one-
step and −0.73 for two-step titration vs. –0.19 for 
placebo; P < 0.0001) and increased the number of 
patients achieving HbA1c <7% (46.5% one-step, 
52.2% two-step, 26.8% placebo) and HbA1c of 
≤6.5% (25.4% one-step, 31.9% two-step, 12.5% 
placebo; P < 0.01) [77].
Several trials have demonstrated the capacity 
of lixisenatide to lower HbA1c as add-on to other 
therapies. For example, as add-on to metformin 
in patients insufficiently controlled on metformin 
alone in two 24-week trials (GetGoal-M and 
GetGoal-F1; one-step and two-step dose 
increase regimens of lixisenatide), lixisenatide 
reduced HbA1c from baseline (HbA1c change 
from baseline [mean baseline HbA1c 8.06%] 
in GetGoal-M –0.87 and –0.38 for lixisenatide 
morning dose and placebo, respectively; 
P < 0.0001) [72] and increased the proportion 
of patients achieving HbA1c goals (GetGoal-F1 
47.4% achieved HbA1c <7% for lixisenatide 
one-step titration vs. 24.1% for placebo 
[P < 0.001] and 25.6% achieved HbA1c <6.5% for 
lixisenatide one-step titration vs. 7.6% for placebo; 
P < 0.0001) [76]. The safety and efficacy of 
lixisenatide once daily in patients inadequately 
controlled on metformin has been compared 
directly with exenatide IR twice daily as add-on 
therapy in the GetGoal-X study [75]. The primary 
objective of this randomized, open-label, 24-week 
trial was to demonstrate noninferiority of 
lixisenatide 20 µg once daily (n = 318) to exenatide 
10 µg twice daily (n = 316) for HbA1c reduction. 
Lixisenatide did demonstrate noninferiority to 
exenatide IR at the end of the study, the proportion 
of subjects achieving HbA1c <7.0% was comparable 
between treatment groups (48.5 vs. 49.8 
for lixisenatide and exenatide, respectively) [75].
Lixisenatide has also been shown to reduce 
HbA1c levels in patients suboptimally controlled 
on either a sulfonylurea in the GetGoal-S trial [73] 
or a thiazolidinedione in the GetGoal-P trial [74]. 
In both of these 24-week trials, lixisenatide increased 
the proportion of patients achieving HbA1c <7% 
(GetGoal-S 36.4% vs. 13.5%; GetGoal-P 52% vs. 
26%, for lixisenatide and placebo, respectively; 
P < 0.0001) [73, 74].
Body Weight
In the studies of lixisenatide in combination 
with OADs, patients had a mean baseline 
body mass index (BMI) of ≥30 kg/m2 (Table 2) 
and were offered diet and lifestyle counseling 
consistent with international or local guidelines 
for patients with T2DM, in addition to study 
medication. Lixisenatide was associated with 
a weight reduction of approximately 1 kg over 
the 24-week study periods when compared with 
placebo in GetGoal-F1 and GetGoal-S [73, 76]; 
smaller reductions in body weight were evident 
in other studies [72, 74]. In GetGoal-X, mean 
baseline body weight was slightly higher in the 
exenatide group (96.1 vs. 94.0 kg for lixisenatide), 
but mean BMI was similar (Table 2). In this study, 
body weight decreased from baseline in both 
groups: −2.96 kg with lixisenatide once daily and 
−3.98 kg with exenatide twice daily (LS mean 
difference 1.02 kg) [75]. As add-on to OADs, it is, 
therefore, clear that in patients with a high BMI, 
lixisenatide has beneficial effects on body weight.
Gastrointestinal and Other Adverse Events
Across these studies, lixisenatide was 
generally well tolerated. As monotherapy, 
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treatment-emergent AEs were comparable for 
lixisenatide and placebo (53.6% vs. 45.1%). 
There were no reports of suspected pancreatitis 
and no instances of lipase or amylase elevation as 
monotherapy [77]. AEs were also similar between 
lixisenatide and placebo as add-on to metformin 
in GetGoal-F1 (68%, 71%, and 66% lixisenatide 
one-step titration, two-step titration and placebo, 
respectively) and GetGoal-M (69.4% for the 
lixisenatide morning injection and 60% for 
placebo) [72, 76], as add-on to thiazolidinediones 
(72.4% and 72.7%) and as add-on to sulfonylureas 
with or without metformin (68.3% and 61.1%). 
In the latter study, one patient in the lixisenatide 
group died as a result of a cardiac event after 
17 days’ exposure to lixisenatide [73].
As monotherapy, 32.2% of lixisenatide-treated 
patients reported gastrointestinal AEs compared 
with 13.9% for placebo, with nausea being the 
most frequent (22.2% vs. 4.1%, respectively) [77]. 
The majority of these events were “mild to 
moderate” in intensity and resolved without the 
need for treatment [77]. As add-on to metformin 
in GetGoal-F1, gastrointestinal events were 
reported in a higher proportion of patients − 
41.6%, 47.2%, and 21.9% for lixisenatide one-
step titration, two-step titration and placebo, 
respectively [76], but were relatively lower in 
GetGoal-M as add-on to metformin, in which 
nausea and vomiting were reported in 22.7% 
and 9.4% for the lixisenatide morning injection 
and 7.6% and 2.9% for placebo, respectively [72]. 
Comparable gastrointestinal tolerability was evident 
in GetGoal-S (as add-on to sulfonylureas with or 
without metformin) with an incidence of 40.9% 
for lixisenatide and 20.0% for placebo [73]. As 
add-on to thiazolidinediones in GetGoal-P, rates for 
nausea, diarrhea, and vomiting were relatively low 
(23.5%, 7.1%, and 6.8% for lixisenatide vs. 10.6%, 
10.6%, and 3.7% for placebo, respectively) [74]. 
Gastrointestinal tolerability also appeared better 
for lixisenatide compared with exenatide in 
GetGoal-X, in which nausea, vomiting, and 
diarrhea were reported in 24.5%, 10.1%, and 10.4% 
for lixisenatide and 35.1%, 13.3%, and 13.3% for 
exenatide, respectively (<0.05 for nausea) [75]. 
Therefore, across these studies, the incidence of 
gastrointestinal events with lixisenatide was of the 
order expected for available GLP-1 receptor agonists, 
and these events often resolve without the need for 
specific treatment. The effect of lixisenatide on heart 
rate has been evaluated in several studies. In a direct 
comparison between lixisenatide and liraglutide, 
lixisenatide treatment was associated with a heart 
rate reduction of 3.6 beats per min (bpm), whereas 
liraglutide administration resulted in an increase in 
heart rate of 5.3 bpm [52]. The ongoing Evaluation 
of LIXisenatide  in Acute Coronary Syndrome 
(ELIXA) study (ClinicalTrials.gov #NCT01147250) 
aims to evaluate the cardiovascular risk profile 
of lixisenatide in patients with T2DM who have 
recently experienced a cardiac event.
Hypoglycemia
Across the GetGoal studies, there was a low 
incidence of symptomatic hypoglycemia. As 
monotherapy, symptomatic hypoglycemia (defined 
as symptoms consistent with hypoglycemia, 
with accompanying blood glucose <3.3 mmol/L 
and/or prompt recovery with carbohydrate) 
were reported in four of 239 (1.7%) lixisenatide-
treated patients and two of 122 (1.6%) patients 
receiving placebo [77]. As add-on to metformin, 
cases of symptomatic hypoglycemia were three of 
161 (1.9%), four of 161 (2.5%), and one of 160 
(0.6%) for lixisenatide one-step titration, two-step 
titration and placebo, respectively in GetGoal-FI 
[76], and 2.4% with a lixisenatide morning 
injection and 0.6% with placebo in GetGoal-M 
[72]. In GetGoal-S (as add-on to sulfonylureas 
with or without metformin), the incidence of 
symptomatic hypoglycemia was higher, as would 
be expected: 88 of 574 (15%) and 35 of 285 (12%) 
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for lixisenatide and placebo, respectively, and 
there was one case of severe hypoglycemia with 
lixisenatide [73]. As add-on to thiazolidinediones 
in GetGoal-P, symptomatic hypoglycemia was 
reported in 11 of 320 (3.4%) with lixisenatide and 
two of 159 (1.2%) with placebo [74]. In GetGoal-X, 
six-times fewer patients experienced hypoglycemic 
events (eight vs. 48 patients) and three-times 
fewer patients experienced symptomatic 
hypoglycemia (eight patients with lixisenatide 
vs. 25 patients with exenatide); there were no 
cases of severe hypoglycemia in either group [75]. 
These data accordingly confirm the low risk of 
hypoglycemia with lixisenatide, which may 
potentially be even lower than that associated 
with exenatide IR.
Lixisenatide in Combination with Basal 
Insulin
To investigate whether the pronounced 
reduction in postprandial glycemic excursions 
observed with lixisenatide could complement 
the fasting glucose control provided by 
basal insulin therapy, two randomized, 
placebo-controlled, 24-week trials and 
a third randomized, placebo-controlled 
trial with a 24-week treatment period 
followed by an extension phase of at least 
52 weeks, have evaluated lixisenatide as add-on 
in patients suboptimally controlled on basal 
insulin for two of the studies (GetGoal-L and 
GetGoal-L-Asia) or on standard antidiabetic 
therapy in one study (GetGoal-Duo-1). In all of 
those studies, lixisenatide decreased both HbA1c
and prevented weight gain, or induced weight 
loss when compared with placebo [62, 70, 71].
Lixisenatide as Add-On to Basal Insulin and 
Metformin
The GetGoal-Duo-1 study was undertaken in 
patients suboptimally controlled on OADs. 
It consisted of a 12-week run-in period 
with introduction and titration of insulin 
glargine to a target FPG of 80−100 mg/dL and 
a 24-week treatment period during which 
446 patients received either lixisenatide or 
placebo in combination with insulin glargine and 
metformin with or without a thiazolidinedione. 
Insulin glargine was also continuously titrated 
during this period. During the 12-week run-in 
period, the addition and titration of insulin 
glargine resulted in a decrease in HbA1c of 
approximately 1%. The addition of lixisenatide 
led to a significantly greater HbA1c decrease of 
0.71% in the lixisenatide group compared with 
0.40% in the placebo group (LS mean difference 
−0.32%; 95% confidence interval [CI] −0.46 
to −0.17; P < 0.0001) (Fig. 4a) [71]. At the end 
of the 24-week treatment period, 56.3% of 
the lixisenatide patients achieved an HbA1c of 
<7% compared with 38.5% in the placebo group 
[71]. Lixisenatide also improved 2-h PPG after a 
standardized breakfast (LS mean difference −3.16; 
95% CI −3.95 to −2.37 mmol/L; P < 0.0001) 
(Fig. 4b). FPG increased moderately from 
baseline to week 24 for both lixisenatide and 
placebo (LS mean change from baseline 0.34 and 
0.46 mmol/L, respectively; P = not significant).
Lixisenatide as Add-On to Basal Insulin With 
or Without Metformin
Comparable observations were seen in 
GetGoal-L, in which lixisenatide 20 µg once 
daily was added on in 495 patients with T2DM 
suboptimally controlled on a combination of 
basal insulin (mean previous insulin therapy, 
55 U/day) with or without metformin [70]. 
When compared with placebo, lixisenatide
reduced HbA1c, the proportion of patients 
achieving HbA1c <7% (28% vs. 12%, 
P < 0.0001) and 2-h PPG after a standardized 
breakfast (LS mean difference −3.81, 
95% CI −4.70 to −2.93; P < 0.0001).
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Lixisenatide as Add-On to Basal Insulin With 
or Without Sulfonylurea in Asian Patients
GetGoal-L-Asia evaluated the effect of lixisenatide 
in 311 Asian T2DM patients not achieving glycemic 
control with basal insulin with or without a 
sulfonylurea [62]. Similar to the other two studies of 
lixisenatide as add-on to basal insulin, the addition 
of lixisenatide 20 µg once daily improved HbA1c
(LS mean difference vs. placebo −0.88%; 
P < 0.0001), the proportion of patients achieving HbA1c
<7% (35.6% vs. 5.2%) and ≤6.5% (17.8% vs. 1.3%) 
(P < 0.0001 vs. placebo), 2-h PPG and glucose 
excursion, and FPG.
Gastrointestinal and Other Adverse Events
Overall, AEs were similar for lixisenatide and placebo 
as add-on to basal insulin. In GetGoal-Duo-1, 
AEs were reported by 80% of lixisenatide-treated 
patients and 68% of placebo-treated patients [71]. 
In GetGoal-L, the incidence of AEs and serious 
AEs was reported to be 73.5% and 3.7% for 
lixisenatide and 68.3% and 4.2% for placebo [70]. 
No information is yet available about the 
incidence of cardiovascular events from these 
studies. In GetGoal-L-Asia, the frequency of serious 
treatment-emergent AEs was similar in the two 
groups: 6.5% in the lixisenatide group and 5.7% in 
the placebo group. However, two patients (1.3%) 
in the lixisenatide group experienced treatment-
emergent AEs of cerebrovascular infarction 
(nonfatal ischemic stroke) [62].
The incidence of gastrointestinal events with 
lixisenatide in combination with basal insulin 
was similar to that observed in combination with 
OADs, although in Asian patients, the rate was 
slightly higher. In GetGoal-Duo-1, nausea, and 
vomiting were the most common gastrointestinal 

























































Fig. 4  Changes in (a) HbA1c, and (b) 2-h postprandial glucose aer 24 weeks of treatment with lixisenatide 20 µg once daily 
or placebo as add-on to basal insulin glargine in patients (n = 466) with T2DM inadequately controlled on metformin with 
or without sulfonylurea with or without thiazolidinediones in the GetGoal-Duo-1 study. Lixisenatide reduced both HbA1c 
and 2-h PPG versus placebo. BL baseline, HbA1c glycated hemoglobin, LS least squares, PPG postprandial plasma glucose, 
T2DM type 2 diabetes mellitus
(a) (b)
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and 1.3% for placebo, respectively) [71]. In 
GetGoal-L, nausea, vomiting, and diarrhea were 
reported in 26.2%, 8.2%, and 7.3% of patients 
receiving lixisenatide and 8.4%, 0.6%, and 5.4% 
of patients receiving placebo, respectively [70]. 
In GetGoal-L-Asia, rates for nausea and vomiting 
were 39.6% and 18.2% versus 4.5% and 1.9% 
for lixisenatide and placebo, respectively [62]. 
Accordingly, as add-on treatment to basal insulin, 
these data indicate that lixisenatide has a good 
overall tolerability profile, with nausea being the 
most common gastrointestinal AE.
Hypoglycemia
The incidence of symptomatic hypoglycemia 
was similar to, or only slightly increased, over 
placebo across these studies. As expected, in 
patients receiving sulfonylureas, the incidence 
of symptomatic hypoglycemia was higher 
than in those not treated with these drugs. In 
GetGoal-Duo-1, a total of 22.4% of patients 
experienced symptomatic hypoglycemia with 
lixisenatide versus 13.5% for placebo [71]. 
In GetGoal-L, the incidence of symptomatic 
hypoglycemia was similar between groups 
(27.7% for lixisenatide vs. 21.6% for placebo), 
but four cases of severe hypoglycemia 
occurred in the lixisenatide group [70]. 
In GetGoal-L-Asia, the incidence of symptomatic 
hypoglycemia was more frequent with lixisenatide 
versus placebo (42.9% vs. 23.6%), but in patients 
not receiving sulfonylureas, the incidence was 
similar between groups (32.6% vs. 28.3%) [62].
Effect of Lixisenatide on Body Weight
As add-on to basal insulin, lixisenatide had a 
beneficial effect on body weight. In GetGoal-
Duo-1, body weight increased by 1.2 kg in the 
placebo group and 0.3 kg in the lixisenatide group 
(LS mean difference –0.9 kg; P = 0.0012) [71]. 
In GetGoal-L, body weight decreased by 1.80 kg 
in the lixisenatide group and 0.52 kg in the 
placebo group (LS mean difference –1.28 kg; 
P < 0.0001) [70]. In GetGoal-L-Asia, the cohort 
had a lower baseline BMI (Table 2), but there 
was still a trend towards weight loss with 
lixisenatide compared with placebo (LS mean 
change −0.38 vs. +0.06 kg, respectively; P = not 
significant) [62].
Lixisenatide in Specific Patient Populations
A subanalysis of 379 patients aged ≥65 years 
(including 48 patients aged ≥75 years) from the 
GetGoal program has demonstrated that the 
efficacy and safety of lixisenatide, including 
hypoglycemia and gastrointestinal events, 
was similar regardless of age, with comparable 
decreases in HbA1c in those ≥65 years of age and 
≥75 years of age, and greater decreases versus 
placebo in both age categories [78]. Data in 
patients with renal, cardiac, or hepatic failure 
are hitherto limited. In individuals without 
diabetes, mild to moderate renal impairment 
did not appear to affect the pharmacokinetics or 
safety of lixisenatide (5 µg dose). In individuals 
with severe renal impairment, drug exposure 
was increased, suggesting that dose adjustment 
may be required in this population [79]. A large 
randomized, controlled study (ELIXA) to evaluate 
the effects of lixisenatide in patients with T2DM 
who have recently experienced an acute coronary 
syndrome event is currently underway.
CONCLUSIONS
Lixisenatide is a novel “short-acting” once-
daily prandial GLP-1 receptor agonist that in 
pharmacokinetic and pharmacodynamic studies 
has been demonstrated to restore the first and 
second-phase insulin responses, accelerate glucose 
disposition, and slow gastric emptying. Despite 
its relatively short half-life, lixisenatide is suitable 
for once-daily dosing, at least partly reflecting 
its marked ability to delay gastric emptying [68]. 
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Lixisenatide once daily has undergone extensive 
clinical evaluation in the phase 3 trial program, 
GetGoal. These clinical data have demonstrated 
that lixisenatide is generally well tolerated 
in patients with T2DM, with possibly better 
gastrointestinal tolerability and a lower risk of 
hypoglycemia than exenatide IR [75]. As with 
other GLP-1 receptor agonists, lixisenatide reduces 
HbA1c, but unlike liraglutide and exenatide LAR, 
has particular efficacy to minimize postprandial 
glucose excursions. The efficacy of lixisenatide in 
glucose-lowering (HbA1c) has been demonstrated 
as monotherapy, in combination with OADs, 
and in combination with basal insulin. In the 
direct comparison with exenatide IR as add-on to 
metformin, lixisenatide demonstrated noninferior 
efficacy in reducing HbA1c [75].
The use of GLP-1 receptor agonists, such as 
lixisenatide, in combination with basal insulin 
is of particular interest and is likely to represent 
an important therapeutic advance for patients 
with T2DM, providing improvements in 
glycemic control while reducing body weight or 
preventing weight gain, without increasing the 
risk of hypoglycemia. In all three GetGoal studies 
as add-on to basal insulin, lixisenatide resulted 
in significant additional improvements in HbA1c
and postprandial glucose control versus placebo, 
as well as a beneficial effect on body weight.
One of the most interesting effects of 
GLP-1 is its ability to slow gastric emptying, 
particularly as the pivotal role of the rate of 
gastric emptying in postprandial glycemic 
control is now appreciated. It appears that 
the longer-acting GLP-1 receptor agonists, 
liraglutide and exenatide LAR, are subject to 
tachyphylaxis for their initial effect to slow 
gastric emptying as a result of more sustained 
receptor activation, while the effect of short-
acting agents is sustained and substantial. 
In line with this, lixisenatide has been 
demonstrated to slow gastric emptying after 
administration for 4 weeks [68], and it is likely 
that the pronounced effect of lixisenatide on 
PPG is mediated, at least partly, by the reduction 
in gastric emptying. In a direct comparison 
with liraglutide, lixisenatide reduced PPG 
excursions much more than the long-acting 
agent [52]. Although once-daily administration 
of lixisenatide in the morning reduces glycemia 
throughout the day, the greatest glucose-
lowering effect appears to occur with the first 
meal, and it would be of interest to determine 
the comparative effects of lixisenatide on 
glycemia when administered with the main 
meal, as opposed to breakfast.
As data emerge from the GetGoal program, it is 
clear that lixisenatide will represent an important 
addition to the options currently available for the 
management of T2DM, with a particular advantage 
over exenatide IR of once-daily administration. 
Lixisenatide is likely to prove to be an excellent 
therapeutic choice in those T2DM patients who 
have relatively faster gastric emptying and, because 
of its pronounced impact on PPG, in patients with 
relatively lower HbA1c, including those already 
receiving basal insulin.
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